Premium
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice 2
Author(s) -
Nishitomi Kouhei,
Sakaguchi Gaku,
Horikoshi Yuko,
Gray Audrey J.,
Maeda Masahiro,
HirataFukae Chiho,
Becker Amanda G.,
Hosono Motoko,
Sakaguchi Isako,
Minami S. Sakura,
Nakajima Yoshihiro,
Li HuiFang,
Takeyama Chie,
Kihara Tsuyoshi,
Ota Akinobu,
Wong Philip C.,
Aisen Paul S.,
Kato Akira,
Kinoshita Noriaki,
Matsuoka Yasuji
Publication year - 2006
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.04178.x
Subject(s) - genetically modified mouse , amyloid precursor protein , transgene , mutant , amyloid precursor protein secretase , endogeny , p3 peptide , wild type , microbiology and biotechnology , bace1 as , chemistry , amyloid (mycology) , enzyme , protein precursor , alzheimer's disease , biochemistry , biology , gene , medicine , disease , inorganic chemistry
Accumulation of amyloid beta peptide (Abeta) in brain is a hallmark of Alzheimer's disease (AD). Inhibition of beta‐site amyloid precursor protein (APP)‐cleaving enzyme‐1 (BACE1), the enzyme that initiates Abeta production, and other Abeta‐lowering strategies are commonly tested in transgenic mice overexpressing mutant APP. However, sporadic AD cases, which represent the majority of AD patients, are free from the mutation and do not necessarily have overproduction of APP. In addition, the commonly used Swedish mutant APP alters APP cleavage. Therefore, testing Abeta‐lowering strategies in transgenic mice may not be optimal. In this study, we investigated the impact of BACE1 inhibition in non‐transgenic mice with physiologically relevant APP expression. Existing Abeta ELISAs are either relatively insensitive to mouse Abeta or not specific to full‐length Abeta. A newly developed ELISA detected a significant reduction of full‐length soluble Abeta 1–40 in mice with the BACE1 homozygous gene deletion or BACE1 inhibitor treatment, while the level of x‐40 Abeta was moderately reduced due to detection of non‐full‐length Abeta and compensatory activation of alpha‐secretase. These results confirmed the feasibility of Abeta reduction through BACE1 inhibition under physiological conditions. Studies using our new ELISA in non‐transgenic mice provide more accurate evaluation of Abeta‐reducing strategies than was previously feasible.